secwatch.observer — SEC 8-K summary
======================================

Issuer:     ANAPTYSBIO, INC (ANAB)
CIK:        0001370053
Form:       8-K
Filed at:   2026-03-03T23:59:59+00:00
Accession:  0001193125-26-088239
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AnaptysBio plans spin-off of biopharma as First Tracks (TRAX); Q4 net income $49.6M
--------------------------------------------------------------------------------

- Spin-off of biopharma portfolio into First Tracks Biotherapeutics (TRAX) on track for Q2 2026, potentially late April.
- Q4 2025 net income $49.6M ($1.79 EPS); full year net loss $13.2M ($0.46 loss per share).
- Collaboration revenue Q4 $108.2M (up from $43.1M); Jemperli royalties $32.7M (+89% YoY).
- GSK Jemperli Q4 sales $343M, annualized ~$1.4B; peak sales guidance >$2.7B; expect >$390M annual royalties.
- Cash $311.6M at year-end; stock repurchased 3.44M shares for $68.6M under program expiring March 31, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1370053/000119312526088239/0001193125-26-088239-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1370053/000119312526088239/anab-20260303.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-088239

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer